Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615491 | 0.88 | NPC1 (0.54) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4743238 | 0.85 | SMN1; SMN2 (0.53) | MAPTRAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL10474999 | 0.85 | RAB9A (0.60) | MAPTRAB9ANPC1USP2TDP1 | |
| SCHEMBL11326015 | 0.84 | RPS6KB2 (0.48) | MAPTRAB9ANPC1USP2TDP1 | |
| SCHEMBL11696564 | 0.82 | NPC1 (0.51) | MAPTRAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL14310604 | 0.81 | RAB9A (0.54) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL11468566 | 0.81 | MAPT (0.54) | MAPTRAB9ANPC1USP2TDP1 | |
| SCHEMBL11333951 | 0.81 | AGPAT2 (0.47) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL9757152 | 0.81 | MAPT (0.60) | MAPTRAB9ANPC1USP2SMN1; SMN2 | |
| SCHEMBL3112570 | 0.80 | NPC1 (0.61) | MAPTRAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-7217820-B2 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-15 | — | — | US | disclosed |
| US-6887460-B2 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-03 | — | — | US | disclosed |
| US-20050089487-A1 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | HEIDENFELDER THOMAS (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030044363-A1 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-06 | — | — | US | disclosed |
| US-4113718-A | Basic azo dyes | CIBA-GEIGY CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | MAPT 389/4885RAB9A 3067/4885NPC1 654/4885 |
| US-20030044363-A1 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | ARSA, AASDHPPT, HRH1 | MAPT 4429/4885RAB9A 4145/4885NPC1 4290/4885 |
| US-20050089487-A1 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | ARSA, AASDHPPT, TYR | MAPT 4363/4885RAB9A 4232/4885NPC1 4416/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | MAPT 1091/4885RAB9A 2995/4885NPC1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.